Display options
Cite
Maiolino G, Azzolini M, Rossi GP. Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!. Front Cardiovasc Med. 2015;2:3doi: 10.3389/fcvm.2015.00003.
Maiolino, G., Azzolini, M., & Rossi, G. P. (2015). Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!. Frontiers in cardiovascular medicine, 23. https://doi.org/10.3389/fcvm.2015.00003
Maiolino, Giuseppe, et al. "Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!." Frontiers in cardiovascular medicine vol. 2 (2015): 3. doi: https://doi.org/10.3389/fcvm.2015.00003
Maiolino G, Azzolini M, Rossi GP. Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!. Front Cardiovasc Med. 2015 Feb 04;2:3. doi: 10.3389/fcvm.2015.00003. eCollection 2015. PMID: 26664875; PMCID: PMC4668865.
Copy Download .nbib Format: NLM
Share it on

Front Cardiovasc Med. 2015 Feb 04;2:3. doi: 10.3389/fcvm.2015.00003. eCollection 2015.

Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!.

Frontiers in cardiovascular medicine

Giuseppe Maiolino, Matteo Azzolini, Gian Paolo Rossi

Affiliations

  1. Department of Medicine (DIMED), Internal Medicine 4, University of Padova , Padova , Italy.

PMID: 26664875 PMCID: PMC4668865 DOI: 10.3389/fcvm.2015.00003

Abstract

Despite the availability of anti-hypertensive medications with increasing efficacy up to 50% of hypertensive patients have blood pressure levels (BP) not at the goals set by international societies. Some of these patients are either not optimally treated or are non-adherent to the prescribed drugs. However, a proportion, despite adequate treatment, have resistant hypertension (RH), which represents an important problem in that it is associated to an excess risk of cardiovascular events. Notwithstanding a complex pathogenesis, an abundance of data suggests a key contribution for the mineralocorticoid receptor (MR) in RH, thus fostering a potential role for its antagonists in RH. Based on these premises randomized clinical trials aimed at testing the efficacy of MR antagonists (MRAs) in RH patients have been completed. Overall, they demonstrated the efficacy of MRAs in reducing BP and surrogate markers of target organ damage, such as microalbuminuria, either compared to placebo or to other drugs. In summary, owing to the key role of the MR in the pathogenesis of RH and on the proven efficacy of MRAs we advocate their inclusion as an essential component of therapy in patients with presumed RH. Conversely, we propose that RH should be diagnosed only in patients whose BP values show to be resistant to an up-titrated dose of these drugs.

Keywords: mineralocorticoid receptor antagonists; pathogenesis; resistant hypertension; review; therapy

References

  1. Diabetes Care. 2007 Jul;30(7):1699-703 - PubMed
  2. Hypertension. 2011 Nov;58(5):811-7 - PubMed
  3. J Clin Endocrinol Metab. 2004 Jun;89(6):2736-40 - PubMed
  4. Hypertens Res. 2011 Jan;34(1):87-90 - PubMed
  5. JAMA. 2003 Apr 23-30;289(16):2073-82 - PubMed
  6. Hypertension. 2008 Jun;51(6):1403-19 - PubMed
  7. Hypertension. 2002 Dec;40(6):892-6 - PubMed
  8. Arch Intern Med. 2008 Nov 24;168(21):2340-6 - PubMed
  9. J Hypertens. 2012 Apr;30(4):633-46 - PubMed
  10. Cardiovasc Res. 2008 Jul 1;79(1):169-78 - PubMed
  11. Eur Heart J. 2013 Jul;34(28):2159-219 - PubMed
  12. Hypertension. 1999 Apr;33(4):981-6 - PubMed
  13. Am J Cardiol. 2014 Feb 15;113(4):687-90 - PubMed
  14. Hypertension. 2003 Dec;42(6):1206-52 - PubMed
  15. Can Med Assoc J. 1983 Jan 1;128(1):31-4 - PubMed
  16. Nat Med. 2012 Sep;18(9):1429-33 - PubMed
  17. J Hypertens. 2013 Jul;31(7):1465-71; discussion 1471-2 - PubMed
  18. Hypertension. 2001 Feb;37(2):187-93 - PubMed
  19. PLoS One. 2012;7(12):e52229 - PubMed
  20. Am J Hypertens. 2005 Jun;18(6):805-12 - PubMed
  21. Hypertension. 2000 Oct;36(4):594-9 - PubMed
  22. Lancet Diabetes Endocrinol. 2014 Dec;2(12):944-53 - PubMed
  23. Nat Clin Pract Nephrol. 2007 Sep;3(9):486-92 - PubMed
  24. J Hypertens. 2007 Apr;25(4):891-4 - PubMed
  25. Clin Ther. 2003 Sep;25(9):2388-404 - PubMed
  26. Kidney Int. 2000 Apr;57(4):1408-11 - PubMed
  27. Am J Cardiol. 1976 Mar 31;37(4):642-9 - PubMed
  28. Hypertension. 2002 May;39(5):982-8 - PubMed
  29. J Endocrinol. 1981 Dec;91(3):457-65 - PubMed
  30. J Am Coll Cardiol. 2011 Feb 1;57(5):590-600 - PubMed
  31. Hypertension. 2011 Jun;57(6):1069-75 - PubMed
  32. J Hum Hypertens. 2010 Jan;24(1):27-33 - PubMed
  33. Lancet. 2002 Mar 23;359(9311):995-1003 - PubMed
  34. Saudi J Kidney Dis Transpl. 2011 Jan;22(1):75-8 - PubMed
  35. N Engl J Med. 2014 Aug 14;371(7):601-11 - PubMed
  36. Lancet. 2009 Apr 11;373(9671):1275-81 - PubMed
  37. Hypertension. 2003 May;41(5):1021-6 - PubMed
  38. Am J Hypertens. 2003 Nov;16(11 Pt 1):925-30 - PubMed
  39. Hypertension. 2014 Nov;64(5):1012-21 - PubMed
  40. Arch Intern Med. 2010 Jan 25;170(2):126-35 - PubMed
  41. Arch Intern Med. 2008 Jun 9;168(11):1159-64 - PubMed
  42. JAMA. 2002 Dec 18;288(23):2981-97 - PubMed
  43. Hypertension. 2004 Jun;43(6):1338-44 - PubMed
  44. JAMA. 2003 Dec 3;290(21):2805-16 - PubMed
  45. Circulation. 1989 Mar;79(3):721-31 - PubMed
  46. Clin Pharmacol Ther. 1978 Nov;24(5):525-30 - PubMed
  47. Am J Cardiol. 2003 Jul 1;92(1):38-42 - PubMed
  48. Ann Intern Med. 1979 May;90(5):783-5 - PubMed
  49. Am J Cardiol. 2004 Apr 15;93(8):990-6 - PubMed
  50. J Hypertens. 2011 Oct;29(10 ):2004-13 - PubMed
  51. JAMA. 1996 May 22-29;275(20):1590-7 - PubMed
  52. Hypertension. 2003 Nov;42(5):878-84 - PubMed
  53. J Hypertens. 2011 Dec;29(12):2295-309 - PubMed
  54. Am J Hypertens. 2005 Nov;18(11):1422-8 - PubMed
  55. Nature. 2000 Sep 7;407(6800):94-8 - PubMed
  56. J Clin Hypertens (Greenwich). 2013 Mar;15(3):186-92 - PubMed
  57. Am J Med. 2009 Mar;122(3):290-300 - PubMed
  58. Am J Med. 2012 Oct;125(10):981-90 - PubMed
  59. Am J Hypertens. 2012 Jan;25(1):1-15 - PubMed
  60. J Hypertens. 2012 Jun;30(6):1211-6 - PubMed
  61. Hypertension. 2011 May;57(5):898-902 - PubMed
  62. Hypertension. 2012 Jun;59(6):1104-9 - PubMed
  63. Hypertens Res. 2014 Dec;37(12):1037-41 - PubMed
  64. Nat Rev Endocrinol. 2011 May 24;7(8):485-95 - PubMed
  65. Eur Heart J. 2013 Apr;34(16):1204-14 - PubMed
  66. J Hypertens. 2010 Jan;28(1):170-7 - PubMed
  67. Circulation. 2009 Jan 27;119(3):371-3 - PubMed
  68. Hypertension. 2005 Oct;46(4):667-75 - PubMed
  69. J Hypertens. 2013 Jan;31(1):3-15 - PubMed
  70. Circulation. 2003 Oct 14;108(15):1831-8 - PubMed
  71. JAMA. 2003 Jul 9;290(2):199-206 - PubMed
  72. Endocrinology. 1986 Feb;118(2):819-23 - PubMed
  73. Hypertension. 2014 Jun;63(6):1212-8 - PubMed
  74. Hypertens Res. 2014 Dec;37(12):1029-31 - PubMed
  75. Hypertension. 2013 Oct;62(4):691-7 - PubMed
  76. Hypertension. 2006 Nov;48(5):787-96 - PubMed
  77. Am Heart J. 2005 Sep;150(3):426-33 - PubMed
  78. J Clin Endocrinol Metab. 2008 Jul;93(7):2566-71 - PubMed
  79. Am J Hypertens. 2002 Aug;15(8):709-16 - PubMed
  80. Hypertension. 2012 Sep;60(3):653-8 - PubMed
  81. BMJ. 2012 Nov 20;345:e7473 - PubMed
  82. J Sleep Res. 2010 Dec;19(4):597-602 - PubMed
  83. PLoS One. 2011;6(9):e24569 - PubMed
  84. Lancet. 2002 Dec 14;360(9349):1903-13 - PubMed
  85. BMJ. 2003 Jun 28;326(7404):1427 - PubMed
  86. Am J Hypertens. 2005 Dec;18(12 Pt 1):1631-5 - PubMed
  87. Am J Hypertens. 2006 Jul;19(7):750-5 - PubMed
  88. Atherosclerosis. 2003 Feb;166(2):345-9 - PubMed
  89. N Engl J Med. 2014 Apr 10;370(15):1393-401 - PubMed
  90. Am J Hypertens. 2012 May;25(5):514-23 - PubMed
  91. Lancet. 2010 Dec 4;376(9756):1903-9 - PubMed
  92. Eur Heart J. 2013 Apr;34(16):1175-7 - PubMed
  93. Hypertension. 2014 Jun;63(6):1168-70 - PubMed
  94. J Clin Sleep Med. 2010 Aug 15;6(4):363-8 - PubMed
  95. J Hypertens. 2013 Oct;31(10):2094-102 - PubMed
  96. Am J Hypertens. 2002 Apr;15(4 Pt 1):333-9 - PubMed
  97. J Hypertens. 2010 Oct;28(10):2161-8 - PubMed
  98. Clin Sci (Lond). 2002 Oct;103(4):425-31 - PubMed
  99. J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300 - PubMed
  100. Hypertension. 2010 Jan;55(1):147-52 - PubMed
  101. Hypertension. 2005 Sep;46(3):481-7 - PubMed
  102. J Hypertens. 2012 Aug;30(8):1656-64 - PubMed
  103. Hypertension. 2009 Sep;54(3):475-81 - PubMed
  104. J Clin Pharmacol. 2003 Nov;43(11):1203-10 - PubMed
  105. J Hypertens. 2001 Nov;19(11):2063-70 - PubMed
  106. Am J Med Sci. 1989 Dec;298(6):361-5 - PubMed
  107. Hypertension. 2002 Aug;40(2):117-23 - PubMed
  108. J Am Coll Cardiol. 2003 Apr 2;41(7):1148-55 - PubMed
  109. Hypertension. 2011 Jun;57(6):1076-80 - PubMed
  110. Am J Hypertens. 2005 Dec;18(12 Pt 1):1534-40 - PubMed
  111. Diabetologia. 2004 Nov;47(11):1936-9 - PubMed
  112. J Hum Hypertens. 2002 Nov;16(11):761-70 - PubMed
  113. J Hypertens. 2013 Apr;31(4):766-74 - PubMed
  114. Ann Pharmacother. 2010 Nov;44(11):1762-9 - PubMed
  115. J Hum Hypertens. 2010 Aug;24(8):532-7 - PubMed
  116. Circulation. 2012 Apr 3;125(13):1635-42 - PubMed
  117. Circulation. 2012 Apr 3;125(13):1594-6 - PubMed
  118. Chest. 2007 Dec;132(6):1858-62 - PubMed
  119. Hypertension. 2001 Nov;38(5):1124-9 - PubMed
  120. Heart. 2014 Jun;100(11):855-61 - PubMed
  121. Arch Intern Med. 1998 Jun 8;158(11):1197-207 - PubMed
  122. J Am Coll Cardiol. 2011 Aug 9;58(7):765-73 - PubMed
  123. BMJ. 2011 Aug 25;343 :d4891 - PubMed
  124. Hypertension. 2011 Mar;57(3):556-60 - PubMed
  125. Hypertension. 2007 Apr;49(4):839-45 - PubMed
  126. Hypertension. 2014 Sep;64(3):501-7 - PubMed
  127. N Engl J Med. 2008 Dec 4;359(23):2417-28 - PubMed

Publication Types